Executive Director and Professor of Medicine
CPC Clinical Research
Aurora , Colorado, United States
Marc Bonaca, MD, MPH, is a cardiologist and vascular medicine specialist serving as Executive Director of CPC and Director of Vascular Research & Professor of Medicine at the University of Colorado Anschutz.
Earned his medical degree from the University of Connecticut and MPH at Harvard. Completed medical residency, cardiology and vascular medicine fellowship at Brigham and Women’s Hospital and research fellowship at the TIMI Study Group. Became faculty at BWH and Harvard Medical School and an investigator at TIMI. Directed pharmacovigilance at TIMI and an investigator on large outcomes trials including TRA2P-TIMI 50, PEGASUS-TIMI 54, DECLARE-TIMI 58, and REAL TIMI 63B.
In 2018, joined the faculty at the University of Colorado as Professor of Medicine and the William R. Hiatt Endowed Chair in Cardiovascular Research. Led several clinical trials as the lead ARO, including VOYAGER PAD, PREVENT HD, ASPEN, and BRIGHT. He' s leading several ongoing trials, EVOLVE MI and MOONRAKER that includes REDEFINE-HF, CONFIRMATION-HF and FINALITY-HF. Clinical and research interests involve improving outcomes and function in patients with PAD. Led PAD focused analyses from data sets including TRA2P-TIMI 50, FOURIER, IMPROVE IT, and CLEAR OUTCOMES. He's the lead author of the STRIDE trial, evaluating semaglutide and functional outcomes in patients with claudication.
His research focuses on ischemic risk with atherosclerotic vascular disease, risk prediction, and risk modification using pharmacologic and biologic therapies. Has extensive experience designing and conducting large, multicenter randomized clinical trials, analyzing registries and real-world datasets.Areas of interest include PAD, PVD, diabetes, with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications, and major adverse cardiovascular events. He investigates the cardiac, vascular, and thrombotic complications associated with novel oncologic therapies. He's focused on building a robust faculty and operational group dedicated to high quality, efficient trials leveraging health networks, informatics, and decentralized design.
Sunday, March 1, 2026
4:45 PM - 4:55 PM MST